 Connection
Timothy McKinsey to Enzyme Inhibitors
This is a "connection" page, showing publications Timothy McKinsey has written about Enzyme Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.490 |
|
|
|
-
Bush EW, McKinsey TA. Targeting histone deacetylases for heart failure. Expert Opin Ther Targets. 2009 Jul; 13(7):767-84.
Score: 0.259
-
Aiello RJ, Bourassa PA, Zhang Q, Dubins J, Goldberg DR, De Lombaert S, Humbert M, Guignabert C, Cavasin MA, McKinsey TA, Paralkar V. Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension. J Pharmacol Exp Ther. 2017 Feb; 360(2):267-279.
Score: 0.109
-
McKinsey TA, Olson EN. Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. J Clin Invest. 2005 Mar; 115(3):538-46.
Score: 0.048
-
Antos CL, McKinsey TA, Dreitz M, Hollingsworth LM, Zhang CL, Schreiber K, Rindt H, Gorczynski RJ, Olson EN. Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J Biol Chem. 2003 Aug 01; 278(31):28930-7.
Score: 0.042
-
Meguro T, Hong C, Asai K, Takagi G, McKinsey TA, Olson EN, Vatner SF. Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ Res. 1999 Apr 02; 84(6):735-40.
Score: 0.032
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|